Ipamorelin: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Ipamorelin is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

Ipamorelin is almost always mentioned as CJC-1295’s partner, and that reputation is well earned — the combination genuinely works better together than either compound alone. But Ipamorelin has its own, more complicated history worth understanding on its own terms, including a detail that surprises a lot of people once they look into it: its only completed human clinical trial had nothing to do with growth hormone, muscle, or anti-aging at all.

Quick Facts

Class	Growth hormone secretagogue (GHRP class)
Receptor target	GHS-R1a (ghrelin receptor)
Administration	Subcutaneous, bedtime fasted
Typical effective range (community-reported)	100mcg–300mcg once daily
Evidence tier	Strong preclinical selectivity data; one completed human RCT, for an unrelated indication, which failed its primary endpoint
Regulatory status	Not approved anywhere; removed from FDA Category 2 in April 2026 but not placed in Category 1, pending PCAC review

The Story So Far

Ipamorelin was developed by Novo Nordisk in the late 1990s, carrying the internal research designation NNC 26-0161. It’s a synthetic pentapeptide — five amino acids — derived from an earlier growth hormone-releasing peptide called GHRP-1, developed specifically to address a problem with that earlier generation of compounds: they worked, but they came with side effects, particularly unwanted elevation of cortisol and prolactin alongside the intended GH release.

The foundational characterization came from Raun and colleagues at Novo Nordisk, published in the European Journal of Endocrinology in 1998. Working in pig and rodent models, they described ipamorelin as the first genuinely selective growth hormone secretagogue — one that triggered robust, dose-dependent GH release without meaningfully elevating cortisol, prolactin, ACTH, FSH, LH, or TSH, even at doses more than 200 times higher than what was needed for the GH effect itself. That’s a remarkable selectivity margin, and it’s the finding that built Ipamorelin’s entire reputation as the “clean” GHRP.

Here’s the part of the story that’s genuinely important and frequently left out: Ipamorelin did advance into human clinical trials, but not for anything related to growth hormone, muscle, or aging. The compound was licensed to Helsinn Therapeutics, which tested it in a Phase 2 randomized controlled trial for postoperative ileus — the temporary bowel paralysis that can follow abdominal surgery — investigating whether ipamorelin’s separate gastroprokinetic properties (its effect on gut motility, not GH release) could speed recovery after bowel resection. That trial, run by Beck, Sweeney, and McCarter and published in the International Journal of Colorectal Disease in 2014, enrolled 114 patients and failed to meet its primary endpoint. Novo Nordisk discontinued clinical development shortly after.

That’s the entire completed human efficacy trial history for this compound: one Phase 2 study, testing an indication almost entirely unrelated to why researchers use ipamorelin today, which didn’t work. It’s a very different picture from “ipamorelin has been studied in humans and shown to work” — a claim that circulates constantly in commercial material but doesn’t hold up against what was actually tested and what actually happened.

From there, Ipamorelin moved into the same research-chemical and compounding-pharmacy channels as CJC-1295. The FDA finalized its Category 2 compounding classification for Ipamorelin in September 2023, alongside CJC-1295. In April 2026, it was removed from Category 2 as part of the same broader reclassification wave — but, as with CJC-1295, it was not placed into Category 1, and currently sits in the same unclassified regulatory gap pending the Pharmacy Compounding Advisory Committee’s July 2026 review. Ipamorelin was also specifically named in Health Canada’s April 2026 advisory on unauthorized injectable peptides.

Worth knowing directly from the source: an FDA briefing document prepared for the Pharmacy Compounding Advisory Committee in late 2024 stated plainly that the agency did not identify any clinical studies evaluating ipamorelin for the indications it’s actually being used for in practice — noting that it’s offered extensively through medical spas and wellness clinics, often without clearly disclosing that what’s being administered is a compounded, unapproved substance.

What It Actually Does

Ipamorelin activates the GHS-R1a receptor — the same receptor ghrelin, the body’s natural “hunger hormone,” binds to — on somatotroph cells in the pituitary gland. That activation triggers a burst of stored growth hormone to be released in a pulse. This is a genuinely different receptor pathway than CJC-1295 uses (which activates the separate GHRH receptor on the same cells), which is exactly why the two are so often combined: two independent signals converging on the same cells produce a larger combined GH pulse than either pathway triggers alone.

Ipamorelin’s defining characteristic, established in that original 1998 pharmacology work, is selectivity. Earlier-generation GHRPs like GHRP-6 and GHRP-2 also release GH, but they do it alongside unwanted increases in cortisol and prolactin, and GHRP-6 specifically also strongly stimulates appetite through the same ghrelin-receptor mechanism. Ipamorelin was specifically developed to keep the GH-releasing activity while minimizing those off-target effects — a real and well-documented pharmacological advantage over its predecessors, independent of the separate question of whether it delivers the downstream outcomes researchers are actually hoping for.

What the Research Shows

This is a compound where being precise about what’s actually been shown matters more than usual, given how often its history gets simplified in one direction or the other.

The preclinical selectivity data is genuinely strong. Raun et al. (1998) and subsequent pharmacology work consistently confirmed dose-dependent GH release without meaningful cortisol, prolactin, ACTH, FSH, LH, or TSH elevation, across animal models. This is real, well-established, peer-reviewed pharmacology — the selectivity claim that anchors most of Ipamorelin’s reputation holds up.

Human data exists, but it doesn’t demonstrate efficacy for GH-related outcomes. Phase 1 dose-escalation studies in healthy volunteers confirmed selective GH release in humans, consistent with the animal data — useful pharmacokinetic and safety information. But the only completed human efficacy trial — the 2014 postoperative ileus study — tested a different mechanism (gastroprokinetic effects) for a different purpose entirely, and it failed to meet its primary endpoint. There is no completed human trial demonstrating that ipamorelin improves body composition, sleep quality, recovery, or any of the outcomes it’s actually researched and used for today.

No post-marketing surveillance data exists at all, since the compound was never approved and marketed as a drug. This means there’s no large-scale, real-world adverse event reporting system tracking ipamorelin the way there is for an approved pharmaceutical — a genuinely different evidence situation than an approved compound like Tesamorelin has.

The honest summary: Ipamorelin’s selectivity — its “clean” profile relative to older GHRPs — is real and well-supported. Its efficacy for the reasons people actually research it today has never been tested in a completed human trial, in either direction. That’s a meaningfully different claim than “it doesn’t work,” and also a meaningfully different claim than “it’s been proven to work.”

How It Compares

Ipamorelin sits alongside CJC-1295 and Tesamorelin in the growth hormone axis category. For the full three-way comparison, see our CJC-1295 guide. What’s specifically distinctive about Ipamorelin within that group:

	Ipamorelin	CJC-1295 (no DAC)	Tesamorelin
Receptor target	GHSR (ghrelin) receptor	GHRH receptor	GHRH receptor
Human trial history	One completed Phase 2 RCT — for gut motility, not GH outcomes; failed primary endpoint	Phase 1 PK data (DAC version only)	Full Phase 3 program; FDA-approved
Key advantage claimed	Selectivity — minimal cortisol/prolactin elevation vs. older GHRPs	Clean, natural pulsatile GH release (no-DAC version)	Only compound in this trio with completed, positive efficacy trials
Regulatory status	Not approved; FDA compounding status in flux	Not approved; FDA compounding status in flux	FDA-approved (Egrifta), for HIV lipodystrophy

The honest positioning across all three: Tesamorelin is the only one with genuine, completed efficacy trials supporting an approved use. Ipamorelin and CJC-1295 both have real, legitimate pharmacology behind their proposed mechanisms, but neither has completed human efficacy data for the outcomes researchers are actually pursuing — and in Ipamorelin’s specific case, the one relevant human trial that was run failed. None of this means the mechanism doesn’t work as proposed; it means the human evidence gap here is real and worth being honest about, rather than papered over with the strength of the animal pharmacology alone.

Who Shouldn’t Use This

Ipamorelin has no approved label, so there’s no official FDA contraindications list. Based on the available literature:

• Personal or family history of cancer or active malignancy. The same theoretical IGF-1-related concern that applies to CJC-1295 and other GH-stimulating compounds applies here.
• Pregnancy or breastfeeding. No human safety data exists in this context.

Unlike CJC-1295, Ipamorelin’s FDA Category 2 classification wasn’t accompanied by a specific, named safety signal in the same way — its restriction reflected the more general “insufficient safety data for compounding” rationale applied broadly. That’s not the same as a clean bill of health; it reflects an absence of the kind of large-scale safety data that would let anyone make a stronger claim in either direction.

Common Myths, Addressed

“Ipamorelin has been proven safe and effective in human trials.” Not accurately. Selectivity — its distinguishing pharmacological feature — has real human data behind it. Efficacy for the outcomes people actually use it for has not been tested in any completed human trial. The one completed efficacy trial tested something else entirely and failed.

“Novo Nordisk abandoned it because it doesn’t work.” Not quite what happened. The trial that failed was testing ipamorelin’s effect on postoperative gut motility — a specific, separate mechanism unrelated to the GH-axis reasons people research it today. A failed trial in one indication doesn’t tell us whether the compound works for a completely different proposed use; it just means that specific question, for that specific indication, didn’t pan out.

“Since it doesn’t raise cortisol or prolactin, it’s essentially risk-free.” Selectivity for those specific side effects is real and valuable, but it isn’t the same as a comprehensive safety profile. The general theoretical concerns around IGF-1 elevation and cancer risk that apply to GH-stimulating compounds broadly still apply here.

What Researchers Are Actually Experiencing

Community-reported experience closely mirrors what’s reported for CJC-1295, which makes sense given how often the two are used together and administered in the same injection.

Timing and fasting matter for the same underlying reason described in our CJC-1295 guide: insulin suppresses the GH axis, so a 2–3 hour fast before bedtime administration is standard community practice.

Increased appetite is reported somewhat more distinctly with Ipamorelin than with CJC-1295, consistent with its activation of the ghrelin receptor — the same receptor responsible for the body’s natural hunger signaling. This is a genuine, mechanistically expected effect rather than an unusual side note.

A full-body warmth or flush following administration is also commonly reported here, the same as with CJC-1295.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Protocol	Research Range	Timing
Once daily	100–300mcg	Bedtime, fasted 2–3 hours
Stacked with CJC-1295	100–300mcg each	Same injection, same timing

Start at 100mcg and work toward 200–300mcg based on response. As with CJC-1295, a well-timed, properly fasted moderate dose is generally considered more productive than a higher dose administered without adequate fasting.

Worked Dose Math

At 2.5mg/mL (a 5mg vial reconstituted with 2mL BAC water — a volume that comfortably fits the standard 3mL vial):

• 100mcg (0.1mg) → 0.04mL → 4 units
• 200mcg (0.2mg) → 0.08mL → 8 units
• 300mcg (0.3mg) → 0.12mL → 12 units

At 5mg/mL (a 10mg vial reconstituted with 2mL BAC water):

• 100mcg (0.1mg) → 0.02mL → 2 units
• 200mcg (0.2mg) → 0.04mL → 4 units
• 300mcg (0.3mg) → 0.06mL → 6 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe. Research ranges here are in micrograms — convert to milligrams before applying the formula. Vendors most commonly sell Ipamorelin in 5mg or 10mg vials, and standard vials hold about 3mL — 2mL of BAC water is a practical, comfortable fill for either size, leaving headroom in the vial.

Vial Planning

A 5mg vial at 2.5mg/mL (reconstituted with 2mL BAC water) gives you 5mg total. At a steady 200mcg/day, that’s 25 days per vial. A 10mg vial at 5mg/mL (also reconstituted with 2mL) doubles that to 50 days from the same fill volume.

Reconstitution and Storage — The Short Version

Ipamorelin reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days. For the complete process, see our dedicated reconstitution and storage guide.

Sourcing

Nothing Ipamorelin-specific beyond the general picture — see our full guide on reading a Certificate of Analysis and vetting a vendor.

Administration

Subcutaneous injection, once daily, bedtime, fasted 2–3 hours. Most researchers administer it in the same injection as CJC-1295 when stacking the two.

Best Practices

• Protect your fasting window — the mechanism this compound depends on is directly tied to it.
• Expect some appetite stimulation as a normal, mechanistically expected effect, particularly if you’re sensitive to ghrelin-pathway activation.
• Pair with CJC-1295 rather than using Ipamorelin alone if your objective is maximizing the GH pulse — this is the combination the mechanism actually supports, and it’s the far more common community approach.
• Track your protocol from day one — dose, timing, fasting duration, and observed effects, at minimum.

Common Mistakes to Avoid

• Treating the selectivity data as proof of efficacy for outcomes that have never actually been tested in a completed human trial.
• Skipping the fasting window, which directly undermines the mechanism this compound depends on.
• Not recording the reconstitution volume, turning every dose calculation into a guess.
• Assuming higher doses produce proportionally larger effects — as with CJC-1295, the pituitary’s own responsiveness, not just compound quantity, governs the size of the resulting GH pulse.

What Happens If You Stop

There’s no dedicated discontinuation research for Ipamorelin, human or otherwise, beyond the single failed postoperative ileus trial, which wasn’t designed to answer this question. As with CJC-1295, because the mechanism amplifies the body’s own pulsatile GH release rather than replacing it directly, there’s no clear reason to expect a withdrawal-style rebound — any downstream effects would reasonably be expected to fade gradually as GH and IGF-1 return toward baseline. This is a reasonable inference from the mechanism, not a documented finding.

What to Expect, Week by Week

• Days 1–7: Appetite changes and the post-injection flush, where reported, tend to appear early.
• Weeks 2–4: Sleep quality and recovery-related community reports tend to consolidate in this window, generally discussed as part of a combined CJC-1295/Ipamorelin protocol rather than Ipamorelin in isolation.
• Weeks 4–8+: Any body composition changes are generally described as gradual, consistent with the indirect, IGF-1-mediated nature of the mechanism.

Individual timelines vary substantially, and — more than for almost any compound in this guide series — this pattern comes entirely from community report, since there’s no completed human trial for any of these specific outcomes to check it against.

Combining With Other Compounds

Ipamorelin’s primary combination is CJC-1295 — the pairing this entire guide keeps returning to, for good mechanistic reason: two separate receptor pathways (GHRH and GHSR) converging on the same pituitary cells produce a larger combined GH pulse than either alone. A pre-blended CJC & Ipamorelin product exists specifically for this combination, covered elsewhere in this guide series. Ipamorelin combined with Tesamorelin instead of CJC-1295 is a less common but documented alternative, generally chosen by researchers specifically interested in Tesamorelin’s more targeted, evidence-backed visceral fat profile.

Common Questions

Has Ipamorelin actually been tested in humans? Yes, but not for the reasons most people research it. Its only completed human efficacy trial tested its effect on gut motility after bowel surgery, and it failed to meet its primary endpoint. Separate Phase 1 studies confirmed its selective GH-release mechanism works in humans, without testing whether that translates into the outcomes researchers actually want.

If its one human trial failed, does that mean it doesn’t work? Not necessarily — that trial tested a different mechanism (gut motility) for a different purpose than why people research this compound today. It means there’s no positive human efficacy trial for that specific indication, not that the GH-related uses have been tested and failed.

Why is Ipamorelin considered “cleaner” than older GHRPs? Because it was specifically developed to trigger GH release without meaningfully raising cortisol, prolactin, or other hormones the way earlier compounds like GHRP-6 and GHRP-2 do — a real, well-documented pharmacological distinction.

Is Ipamorelin legal to buy in Canada? It’s sold as a research-use-only compound, but it was specifically named in Health Canada’s April 2026 advisory on unauthorized injectable peptides. See our full Canadian regulatory guide for what that does and doesn’t mean in practice.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Considered whether you have a personal history of cancer, and sought medical guidance if so
• [ ] Planned your fasting window around your injection timing
• [ ] Decided whether you’re running Ipamorelin alone or stacked with CJC-1295
• [ ] Have a tracking method ready for dose, timing, and observed effects
• [ ] Understand that human efficacy data for this compound’s actual research uses doesn’t currently exist

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose	Frequency
Standard	100–300mcg	Once daily, bedtime fasted
Stacked with CJC-1295	100–300mcg each	Once daily, same injection

Where to Go From Here

• The Growth Hormone Axis Group — CJC-1295, Ipamorelin, and Tesamorelin compared in full
• CJC-1295: The Complete Guide
• CJC & Ipamorelin — the pre-blended combination product
• Our Canadian Regulatory Landscape Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.